pk/pd of vaping thc-containing liquids vs. smoked cannabis

Conditions: Cigarette Smoking-Related Carcinoma

Summary: we will conduct a randomized, within-subjects clinical study to compare short-term pharmacokinetic (pk) and pharmacodynamic (pd) effects of δ9-tetrahydrocannabinol (thc) vaping liquids vs. smoked cannabis containing 6 equivalent standard thc units (5 mg thc=1 standard thc unit (stu)) in healthy community members who are current users of both products. while smoking cannabis remains the most common mode of thc use among adults and youth, alternative modes of delivery, such as electronic vaping products (evps), are becoming increasingly popular for the delivery of cannabinoids. declining cannabis risk perceptions, increasing normalization of cannabis, greater legal access and availability to cannabis, ease of administration, and ability to conceal vaped thc use have likely contributed to increasing prevalence of use throughout the population across all age groups. comparing vaping thc containing liquids with smoking cannabis can serve as an important benchmark for evaluating the delivery and effects of thc vaping products and, their relative safety

primary objective: i. compare the pk/pd profiles of delta-9 tetrahydrocannabinol (thc) from equivalent standard thc doses (30mg) administered as vaped thc liquid vs. smoked cannabis using a within-subject design. secondary objectives: i. safety primary objective: i. compare the pk/pd profiles of delta-9 tetrahydrocannabinol (thc) from equivalent standard thc doses (30mg) administered as vaped thc liquid vs. smoked cannabis using a within-subject design. secondary objectives: i. safety

Eligibility criteria:
inclusion criteria: * age \>= 21 years of age * report concurrent use of commercial (medical or recreational) smoked cannabis and thc vaping cartridges for at least 3 months prior to enrollment * report smoking cannabis and thc- vaping liquid use at the potency level of the study product at least weekly (4x/month) * report of not currently trying to become pregnant (females). women of childbearing potential must be willing to provide a urine sample and test negative prior to receiving any study-related products/procedures * willing to complete a thc saliva test to check for recent use (narcocheck ref#:nce-sthc-1) and semi -quantitative urinary tetrahydrocannabinol-carboxylic acid (thca) rapid test (narcocheck® thc predosage) during baseline testing, prior to receiving any study-related products * participant must understand the investigational nature of this study and sign an institutional review board approved written informed consent form prior to receiving any study related procedure exclusion criteria: * • illegal or non-prescription drug use within the past 90 days. as detected by nacrocheck® évolutive® (detection in human urine of the 12 most currently abused drugs) at the first session and prior to receiving any study product * report 2 or more drinking occasions/week with 4 or more drinks/occasion * report of daily nicotine use * current or prior diagnosis of any psychotic disorders * current or prior diagnosis of chronic heart conditions * current or prior diagnosis of any respiratory condition * pregnant or currently trying to become pregnant (females) * detection level 4-5 (\>300 ng/ml) from a semi-quantitative urinary thca rapid test (narcocheck® thc predosage) * unwilling or unable to follow protocol requirements * any condition which in the investigator's opinion deems the participant an unsuitable candidate for participation